Esperion Therapeutics, Inc.

符号: ESPR

NASDAQ

2.05

USD

今天的市场价格

-0.9875
市盈率
0.0209
PEG比率
349.36M
MRK市值
0.00%
DIV收益率

Esperion Therapeutics, Inc. (ESPR) 财务报表

Q: 什么是 Esperion Therapeutics, Inc. (ESPR) 总资产是多少？

Esperion Therapeutics, Inc. (ESPR) 总资产为 .

Download

年度季度

线性对数

在图表中，您可以看到的动态默认数字 Esperion Therapeutics, Inc. (ESPR). 的默认数据。公司收入显示 341.627 M 的平均值，即 -0.107 % 增长率。整个期间的平均毛利润为 326.092 M，即 0.442 %. 平均毛利率为 -22.771 %. 公司去年的净收入增长率为 -0.273 %，等于 -0.369 % % 整个公司历史的平均增长率.,

年度季度

10Y 20Y 30Y 40Y

资产负债表

深入分析 Esperion Therapeutics, Inc. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 -0.170. 在流动资产领域，ESPR 的报告货币为201.065. 这些资产中的很大一部分，即 82.248 是现金和短期投资。与去年的数据相比，该部分的变化率为-0.341%. 公司的长期投资虽然不是其重点，但以报告货币计算的0（如果有的话）为0。这表明与上一报告期相比，-100.000% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 501.546. 这一数字表明，1.073% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 -454.994. 这方面的年同比变化率为 -0.660%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为48.494，存货估值为 65.62，商誉估值为 0（如有. 无形资产总额（如果有）按 0.06 估值. 应付账款和短期债务分别为 31.72 和 36.38. 债务总额为540.95，债务净额为 458.7. 其他流动负债为 62.72，加上总负债 660.79. 最后，如果存在推荐股票，则其估值为 0.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2002	2000
balance-sheet.row.cash-and-short-term-investments	497.89	82.2	124.8	208.9	305	166.1	37	34.5	38.2	77.3	85	60.1	6.5	1.6	44.9	70.3	70.2	5.9
balance-sheet.row.short-term-investments	17.43	0	42.1	50.4	0	34.7	99	165.7	173.4	134.9	20.8	3.5	0	0	4.4	0	0	0
balance-sheet.row.net-receivables	168.33	48.5	33.7	22.9	12.4	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.inventory	202.09	65.6	35.2	34.4	16.1	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-current-assets	20.89	4.7	9.9	62.8	24.8	10.9	6.6	3.7	2	2.1	0.9	0.6	0.6	0.3	0.4	1	1.1	0.1
balance-sheet.row.total-current-assets	902.02	201.1	246.7	329	345.9	211.7	142.6	203.9	213.6	214.4	106.8	60.6	7.1	1.9	45.3	71.3	71.3	6
balance-sheet.row.property-plant-equipment-net	11.3	4.7	1.2	2.6	7.3	2.7	0.5	0.4	0.7	0.8	0.8	0.1	0.1	0.3	3	3.3	2.5	2
balance-sheet.row.goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.1	3.1	0	0
balance-sheet.row.intangible-assets	0.22	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0	0	3.5	0
balance-sheet.row.goodwill-and-intangible-assets	0.22	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	3.1	3.1	3.5	0
balance-sheet.row.long-term-investments	0	0	42.1	50.4	0	34.7	99.3	239.2	204.3	215.2	56.5	17.5	0	0	0	0	0	0
balance-sheet.row.tax-assets	0	0	0	-50.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	-3.72	0	-42.1	50	-7.4	-34.7	-99	-165.7	-173.4	-134.9	-20.8	0	0	0	0	0.6	0.5	0
balance-sheet.row.total-non-current-assets	11.52	4.7	1.3	52.6	7.4	2.7	0.8	73.9	31.6	81.2	36.6	17.7	0.2	0.3	6.1	7.1	6.5	2
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	913.55	205.8	247.9	381.6	353.3	214.4	143.5	277.8	245.2	295.6	143.3	78.3	7.3	2.2	51.4	78.3	77.9	8
balance-sheet.row.account-payables	99.56	31.7	23	17.6	52	28.9	44.9	20.4	4.6	0.7	2	2.2	0.5	0.7	1.7	2.9	3.9	1.4
balance-sheet.row.short-term-debt	38.29	36.4	0.4	1.4	2.6	0.5	0	1	1.7	1.6	0.6	0	15.2	0	1.1	0.9	0.7	0.5
balance-sheet.row.tax-payables	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0	0	0
balance-sheet.row.long-term-debt-total	1288.3	501.5	260.6	258.8	182.8	1.1	0	0	1	2.7	4.3	0	7.5	6.9	7.7	5.5	3	2.3
Deferred Revenue Non Current	0	0	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	285.83	62.7	65.4	48.7	37.8	34.6	19.4	11.7	9.2	3.3	2.7	2	0.3	0.6	2.2	2.6	2.5	1
balance-sheet.row.total-non-current-liabilities	1983.59	504.6	479.4	505.2	355.3	128.4	0	0	1	2.7	4.3	0	7.5	6.9	7.7	5.5	3	2.3
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	9.46	3	1	1.9	6	1.6	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	2480.18	660.8	571.7	578.5	449.4	194.5	64.3	33.1	16.6	8.3	9.8	4.2	24.7	8.2	12.7	11.8	10.2	5.2
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	78293.9	24	24	0	0	0	0
balance-sheet.row.common-stock	0.42	0.1	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.retained-earnings	-5895.67	-1549.3	-1340	-1106.4	-838.8	-695.3	-598.1	-396.3	-229.2	-154.2	-104.4	-68.1	-42	-30.2	-94	-65.3	-40.4	-12.8
balance-sheet.row.accumulated-other-comprehensive-income-loss	0	0	0	0	0	0	-0.3	-0.8	-0.2	-0.5	-0.1	0	-1.2	-1	-3.7	-2.4	-1.3	-0.5
balance-sheet.row.other-total-stockholders-equity	3256.52	1094.2	-0.1	0	0	-0.1	0.3	641.8	458	441.9	238	-78151.7	1.8	1.2	136.4	134.2	109.3	16.1
balance-sheet.row.total-stockholders-equity	-2638.73	-455	-1340	-1106.4	-838.8	-695.3	-598.1	244.7	228.6	287.3	133.6	74.1	-17.4	-6.1	38.7	66.5	67.7	2.8
balance-sheet.row.total-liabilities-and-stockholders-equity	-158.55	205.8	-768.3	-527.8	-389.4	-500.8	-533.8	277.8	245.2	295.6	143.3	78.3	7.3	2.2	51.4	78.3	77.9	8
balance-sheet.row.minority-interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-equity	-2638.73	-455	-1340	-1106.4	-838.8	-695.3	-598.1	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	-158.55	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	17.43	0	84.2	100.9	0	69.3	99.3	239.2	204.3	215.2	56.5	21.1	0	0	4.4	0	0	0
balance-sheet.row.total-debt	1329.61	540.9	260.9	260.2	185.4	1.6	0	1	2.7	4.3	4.9	0	22.8	6.9	8.8	6.3	3.7	2.8
balance-sheet.row.net-debt	849.15	458.7	136.2	51.3	-119.6	-164.6	-37	-33.4	-35.4	-73	-80.1	-56.5	16.3	5.3	-31.7	-63.9	-66.5	-3.1

现金流量表

在 Esperion Therapeutics, Inc. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 0.225 的转变。该公司最近通过发行 65.97 扩大了股本，与上一年相比出现了57.333 的差异. 有趣的是，公司的部分股票，特别是 0，是由公司自己回购的。这一举动导致0.000 比上一年有所变化。同时，以报告货币计算，公司的应付账款目前为 8.68. 公司的投资活动产生了现金使用净额，按报告货币计算达到42500000.000. 与上一年相比， 4.244 发生了变化. 在同一时期，公司记录了 0.16, 0 和 -15.51，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将0 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 0，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2002	2000
cash-flows.row.net-income	-209.25	-209.2	-233.7	-269.1	-143.6	-97.2	-201.8	-167	-75	-49.8	-36.4	-26.1	-11.7	-10.8	-28.7	-24.9	-27.6	-10.7
cash-flows.row.depreciation-and-amortization	0.16	0.2	0.5	0.6	0.5	0.3	0.3	0.3	0.3	0.2	0.2	0.1	0.1	0.2	-1.3	-2	-2	-0.7
cash-flows.row.deferred-income-tax	-17.56	36.5	0	-2.6	-0.1	-0.2	0	0.3	1	0.7	0.2	2.5	0.1	0.1	0	0	0	0
cash-flows.row.stock-based-compensation	11.96	12	15.2	24.3	28.4	25.9	24	18.6	16	12.7	3.7	1.2	0.1	0.1	0	0	0	0
cash-flows.row.change-in-working-capital	13.68	13.7	-3.4	-52.5	-4.3	-7.3	29.2	16.5	10	-2.1	0.3	3.2	-0.8	0.8	-0.5	-1.1	3	1.9
cash-flows.row.account-receivables	-14.77	-14.8	-10.8	-10.5	-10.7	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-30.42	-30.4	-0.8	-18.3	-16.1	0	0	0	0	0	0	0	0	0	0	0	0	-2.6
cash-flows.row.account-payables	8.68	8.7	5.6	-34.1	23.1	-16.1	24.4	15.8	3.9	-1.3	-0.3	1.8	-0.2	0.6	-1.2	-0.8	2.6	1.3
cash-flows.row.other-working-capital	50.18	50.2	2.6	10.4	-0.5	8.8	4.7	0.7	6.1	-0.8	0.6	1.5	-0.6	0.2	0.8	-0.2	0.4	3.1
cash-flows.row.other-non-cash-items	65.52	11.5	46.5	35.5	33.8	8.1	-0.2	0	0	0.1	0	0.9	1.5	0.6	3.9	5.2	8.7	1.6
cash-flows.row.net-cash-provided-by-operating-activities	-135.49	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	0	0	0	0	-13.4	-1	-0.2	0	-0.1	-0.3	-0.9	0	0	0	-1.2	-2	-1.3	-1.6
cash-flows.row.acquisitions-net	0	0	0	0	12.5	-65.2	0	0	0	0	0	0	0	0	0	0	-0.2	0
cash-flows.row.purchases-of-investments	0	0	-59.9	-50.5	-4.4	-34.3	-25.5	-219.6	-197.2	-280.6	-48.1	-24.7	0	0	-37.2	0	0	0
cash-flows.row.sales-maturities-of-investments	42.5	42.5	68	0	39.1	99.5	166.1	183.7	207.4	120.8	12.4	3.5	0	0.5	32.9	0	0	0
cash-flows.row.other-investing-activites	42.5	0	0	0	-12.5	65.2	0	0	0	0	0	0.2	0	0	0	-0.1	-0.5	0
cash-flows.row.net-cash-used-for-investing-activites	42.5	42.5	8.1	-50.5	21.4	64.2	140.4	-35.9	10.1	-160.1	-36.6	-21	0	0.5	-5.5	-2.1	-2	-1.6
cash-flows.row.debt-repayment	-15.51	-15.5	-58.2	-0.8	-296.1	-124.4	-1	-1.7	-1.6	-0.6	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-issued	13.52	66	90.8	218.7	6.6	11.8	0	164	0	190	91.7	72.2	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	-0.02	0	0	0	-55	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	0	0	0	0	-302.7	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-financing-activites	53.81	0	-50.2	50.3	848.9	248.8	11.7	1.2	0	1.2	5.4	16.9	15.7	6.7	1.4	25	84.1	2.8
cash-flows.row.net-cash-used-provided-by-financing-activities	50.46	50.5	32.6	268.2	201.7	136.2	10.7	163.5	-1.6	190.5	97.1	89.1	15.8	6.7	1.4	25	84.1	2.8
cash-flows.row.effect-of-forex-changes-on-cash	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	-0.1	0.2	0
cash-flows.row.net-change-in-cash	-42.53	-42.5	-134.1	-46.1	137.9	130.1	2.5	-3.7	-39.2	-7.7	28.5	50	4.9	-1.8	-29.8	0.1	64.3	-6.6
cash-flows.row.cash-at-end-of-period	480.46	82.2	124.8	258.9	305	167.1	37	34.5	38.2	77.3	85	56.5	6.5	1.6	40.5	70.3	70.2	5.9
cash-flows.row.cash-at-beginning-of-period	522.99	124.8	258.9	305	167.1	37	34.5	38.2	77.3	85	56.5	6.5	1.6	3.4	70.3	70.2	5.9	12.5
cash-flows.row.operating-cash-flow	-135.49	-135.5	-174.8	-263.8	-85.2	-70.3	-148.6	-131.3	-47.7	-38.2	-32	-18.1	-10.8	-9.1	-26.6	-22.8	-18	-7.9
cash-flows.row.capital-expenditure	0	0	0	0	-13.4	-1	-0.2	0	-0.1	-0.3	-0.9	0	0	0	-1.2	-2	-1.3	-1.6
cash-flows.row.free-cash-flow	-135.49	-135.5	-174.8	-263.8	-98.5	-71.3	-148.8	-131.3	-47.8	-38.5	-32.9	-18.1	-10.8	-9.1	-27.7	-24.8	-19.3	-9.4

利润表行

Esperion Therapeutics, Inc. 的收入与上期相比变化了 0.541%。据报告, ESPR 的毛利润为 72.9。该公司的营业费用为 228.47，与上年相比变化了 0.200%. 折旧和摊销费用为 0.16，与上一会计期间相比变化了 -0.938%. 营业费用报告为 228.47，显示0.200% 的同比变化。销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。基于近期数据的EBITDA为 0，同比增长0.133%. 营业收入为 -155.56，与上年相比变化了-0.133%. 净利润的变化率为 -0.273%。去年的净收入为-209.25.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2002	2000
income-statement-row.row.total-revenue	116.33	116.3	75.5	78.4	227.5	148.4	184.5	0	0	0	0	4977	0	0	0	0	0	0
income-statement-row.row.cost-of-revenue	43.27	43.4	27	14.2	2.4	175.6	0	0	0	0	0	0	0	0	0	0	0.8	0.7
income-statement-row.row.gross-profit	73.06	72.9	48.5	64.2	225.2	-27.2	184.5	0	0	0	0	4977	0	0	0	0	-0.8	-0.7
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	86.11	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	29.82	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	15.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	22.52	5.3	2.7	4	0.5	4.1	2.8	2.2	1.5	0.8	0.1	0.2	-0.1	-0.1	0	0	5	3.2
income-statement-row.row.operating-expenses	248.79	228.5	228	291	346.6	241.5	204.6	169	76.2	50	36.2	22.8	10.2	10.2	29.2	29.3	26.8	11.7
income-statement-row.row.cost-and-expenses	271.9	271.9	255	305.2	348.9	241.5	204.6	169	76.2	50	36.2	22.8	10.2	10.2	29.2	29.3	27.6	12.4
income-statement-row.row.interest-income	5.11	4.8	2.6	0.1	0.6	4	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.interest-expense	-0.09	59	56.8	46.4	22.7	8.1	0.1	0.2	0.4	0.5	0.3	0.9	1.5	0.6	0	0	0	0
income-statement-row.row.selling-and-marketing-expenses	15.6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	-53.69	-53.7	-54.2	-42.4	-22.2	-4.1	2.8	2.2	1.5	0.8	0.1	-2.4	-0.1	-0.1	-0.7	0.3	-3.8	0
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	22.52	5.3	2.7	4	0.5	4.1	2.8	2.2	1.5	0.8	0.1	0.2	-0.1	-0.1	0	0	5	3.2
income-statement-row.row.total-operating-expenses	-53.69	-53.7	-54.2	-42.4	-22.2	-4.1	2.8	2.2	1.5	0.8	0.1	-2.4	-0.1	-0.1	-0.7	0.3	-3.8	0
income-statement-row.row.interest-expense	-0.09	59	56.8	46.4	22.7	8.1	0.1	0.2	0.4	0.5	0.3	0.9	1.5	0.6	0	0	0	0
income-statement-row.row.depreciation-and-amortization	1.36	0.2	2.7	4	0.5	4.1	0.3	0.3	0.3	0.2	0.2	0.1	0.1	0.2	-1.3	-2	-2	-0.7
income-statement-row.row.ebitda-caps	-154.28	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-155.56	-155.6	-179.5	-226.7	-121.4	-93.1	-204.6	-169	-76.2	-50	-36.2	-22.8	-10.2	-10.2	-27.9	-27.3	-27.6	-12.4
income-statement-row.row.income-before-tax	-209.25	-209.2	-233.7	-269.1	-143.6	-97.2	-201.8	-167	-75	-49.8	-36.4	-26.1	-11.7	-10.8	-28.7	-24.9	-31.4	0
income-statement-row.row.income-tax-expense	27.42	0	54.2	49.7	22.6	11.9	2.9	2.1	1.7	1.1	0.2	1.1	1.4	0.5	2.1	0.5	4.1	-0.3
income-statement-row.row.net-income	-236.75	-209.2	-287.8	-318.8	-166.2	-109	-201.8	-167	-75	-49.8	-36.4	-26.1	-11.7	-10.8	-28.7	-24.9	-27.6	-10.7